MA27493A1 - Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges - Google Patents

Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges

Info

Publication number
MA27493A1
MA27493A1 MA28292A MA28292A MA27493A1 MA 27493 A1 MA27493 A1 MA 27493A1 MA 28292 A MA28292 A MA 28292A MA 28292 A MA28292 A MA 28292A MA 27493 A1 MA27493 A1 MA 27493A1
Authority
MA
Morocco
Prior art keywords
controlled
pharmaceutical compositions
treatment agent
sustained release
compositions containing
Prior art date
Application number
MA28292A
Other languages
English (en)
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/278,912 external-priority patent/US20030114394A1/en
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MA27493A1 publication Critical patent/MA27493A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSITIONS PHARMACEUTIQUES A LIBERATION MAITRISEE ET PROLONGEE RENFERMANT DES POLYMERES CHARGES La présente invention se rapporte à un système de délivrance de compositions pharmaceutiques qui se fonde en partie sur une interaction ionique pour maîtriser et faciliter la libération de l'agent de traitement. Plus spécifiquement, l'invention se rapporte à un système de libération maîtrisée et prolongée possédant un agent de traitement ionique et un polymère ionique, oé le polymère est suffisamment ionisé pour libérer l'agent de traitement de façon maîtrisée sur une période prolongée et la composition ne requiert pas de système d'émulsion pour l'administration de l'agent de traitement.
MA28292A 2002-10-24 2005-05-20 Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges MA27493A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/278,912 US20030114394A1 (en) 2001-10-29 2002-10-24 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US43850103P 2003-01-08 2003-01-08

Publications (1)

Publication Number Publication Date
MA27493A1 true MA27493A1 (fr) 2005-08-01

Family

ID=32179474

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28292A MA27493A1 (fr) 2002-10-24 2005-05-20 Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges

Country Status (23)

Country Link
EP (1) EP1556015B1 (fr)
JP (1) JP5204374B2 (fr)
KR (1) KR20050083802A (fr)
CN (2) CN101327326A (fr)
AR (1) AR039464A1 (fr)
AU (1) AU2003233066B2 (fr)
BR (1) BR0315576A (fr)
CA (1) CA2503383C (fr)
CO (1) CO5700711A2 (fr)
ES (1) ES2618300T3 (fr)
HR (1) HRP20050448A2 (fr)
MA (1) MA27493A1 (fr)
ME (2) ME00233B (fr)
MX (1) MXPA05004330A (fr)
NO (1) NO20052480L (fr)
NZ (1) NZ539512A (fr)
PE (2) PE20081613A1 (fr)
PL (1) PL376537A1 (fr)
RS (1) RS20050321A (fr)
RU (2) RU2366410C2 (fr)
TW (1) TW200406223A (fr)
WO (1) WO2004037229A1 (fr)
ZA (1) ZA200503133B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122022A2 (fr) * 2005-05-10 2006-11-16 Novartis Ag Compositions pharmaceutiques de famciclovir a liberation modifiee
WO2017130208A1 (fr) * 2016-01-29 2017-08-03 Faheem Hyder Pottoo Association de trois médicaments pour le traitement d'un état de mal épileptique et/ou de crises partielles et/ou de crises partielles avec des troubles neurologiques associés

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615697A (en) * 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу

Also Published As

Publication number Publication date
CN1703205A (zh) 2005-11-30
HRP20050448A2 (en) 2005-12-31
WO2004037229A1 (fr) 2004-05-06
EP1556015B1 (fr) 2017-02-22
RU2366410C2 (ru) 2009-09-10
ME00233B (fr) 2011-05-10
NO20052480L (no) 2005-07-25
CA2503383A1 (fr) 2004-05-06
RU2005115574A (ru) 2005-10-27
PE20040323A1 (es) 2004-06-10
AU2003233066B2 (en) 2009-11-19
PE20081613A1 (es) 2008-11-15
AU2003233066A1 (en) 2004-05-13
CO5700711A2 (es) 2006-11-30
MEP34108A (en) 2011-02-10
RU2009112072A (ru) 2010-10-10
RS20050321A (en) 2007-08-03
KR20050083802A (ko) 2005-08-26
CA2503383C (fr) 2013-03-12
MXPA05004330A (es) 2005-08-02
NO20052480D0 (no) 2005-05-23
AR039464A1 (es) 2005-02-23
JP5204374B2 (ja) 2013-06-05
ZA200503133B (en) 2006-12-27
ES2618300T3 (es) 2017-06-21
PL376537A1 (pl) 2006-01-09
EP1556015A1 (fr) 2005-07-27
CN101327326A (zh) 2008-12-24
CN1703205B (zh) 2010-12-01
BR0315576A (pt) 2005-08-30
NZ539512A (en) 2009-03-31
TW200406223A (en) 2004-05-01
JP2006506453A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
EA200100872A1 (ru) Композиция валдекоксиба
DE59510866D1 (de) Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
FR2814678B1 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
DK0812208T3 (da) Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer
BR0001504A (pt) Plástisóis de poliaquil metacrilato com propriedades de escoamento aperfeiçoadas
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
BR0209616A (pt) Composição de resina termoplástica
DE50107641D1 (de) Überzugs- und bindemittel für arzneimittelformulierungen mit verbesserter lagerstabilität
YU39400A (sh) Kombinacije opijatni agonist/antagonist
SV2002000581A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester ref.pc10754/700005/bb
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BR0213143A (pt) Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
SE9300581D0 (sv) Komposition foer nasalbehandling
BR9902643A (pt) Emulsão de óleo de silicone, composição e método de fabricação
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
SI1073456T1 (sl) Uporaba osteoprotegerina za preventivo pred kardiovaskularnimi boleznimi in za njihovo zdravljenje
MA27493A1 (fr) Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges
DE60116662D1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
BR9902377A (pt) Composição para toner e processos para a mesma.
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
MA27591A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.